The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m2 in Japan and Europe. Although lower doses are established alternatives based on randomized controlled trials, the safety and efficacy of 25 and 20 mg/m2 in real-world settings are not well established. | Real-world efficacy and safety of two doses of cabazitaxel 20 or 25 mg m2 in patients with castration-resistant prostate cancer Results of a Japanese post-marketing surveillance study
